Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123
Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises the price target from $92 to $123.
Share
Why It Matters
A big bank analyst thinks Haemonetics is now a good company to own. They raised their price guess from $92 to $123 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.